Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta
No Definitive Decision Yet On Avenue Deal
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.
You may also be interested in...
Executive vice chairperson of Cipla Samina Hamied talks to Generics Bulletin about the company’s intention to become global lung leaders on the back of biosimilars opportunities and its inhalation assets. As well as discussing Cipla’s three-year strategy, Hamied – who is also the vice president of IPA – discusses creating a favorable regulatory and policy landscape in India.
Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential for significant cost savings for the UK’s National Health Service.
Endo’s Par looks set to provide much needed supply in the US market for varenicline tablets, after originator Pfizer ran into supply and distribution problems due to the presence of a nitrosamine for its Chantix original.